Publication
Title
Telaprevir : efficacy and safety
Author
Abstract
Standard of care treatment of chronic hepatitis C genotype 1 virus infection with pegylated interferon and ribavirin has been associated with rates of treatment success of only 50%. Telaprevir is one of the first NS3/4A protease inhibitors which, in combination with pegylated interferon and ribavirin, leads to higher rates of sustained viral response. Telaprevir has been approved for treatment-naïve and experienced patients with chronic HCV genotype 1 infection. Current clinical limitations include high rates of adverse events, long treatment duration and unclear use in special populations such as transplant patients and HIV coinfected patients. Future research will need to clarify these clinical obstacles and look for other treatment options.
Language
English
Source (journal)
Journal of symptoms and signs
Publication
2014
Volume/pages
3:1(2014), p. 16-25
Full text (publisher's version - intranet only)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Record
Identification
Creation 10.04.2014
Last edited 02.10.2015
To cite this reference